Decreasing Multidrug-Resistant Bacteria Levels
Burn injuries are associated with high mortality associated with infections, especially those who suffer extensive burns that cover 40% or more of the body. Pseudomonas aeruginosa is one of the most lethal pathogens, found in approximately 33% of all burn cases and in 59% of extensive burns. Researchers from the Southwestern Medical Center in San Antonio showed that topical application of an engineered adhesion inhibitor molecule, Multivalent Adhesion Molecule 7, substantially decreased the multidrug-resistant Pseudomonas aeruginosa levels in wounds in the first 24 hours after administration. The molecules also prevented the spread of the infection to adjacent tissue for 3 days and aided wound healing by maintaining normal inflammatory responses. The new approach targets the microbes' ability to bind, or stick, to cells in an early and crucial step in causing infection.
FDA Approves PolyPlex Wound Dressing
Global Health Solutions has secured 510(k) clearance from the FDA for its PolyPlex wound dressing. PolyPlex is a petrolatum-based topical gel that features the company's PermaFusion delivery system to provide protection against bacteria, fungi, and yeasts without irritation to fragile and healing tissue. It is indicated for acute and chronic wound management. Petrolatum base may promote moist wound healing with minimal risk of causing maceration wounds like hydrogels. PermaFusion delivery system is also used in the firm's other wound dressing product, CurX antimicrobial gel.
Evaluating Pain Management with Topical Analgesics
Clarity, an international scientific research company based in Austin, Texas, has released the results of a study titled, "Optimizing Patient Experience and Response to Topical Analgesics". The study was intended to evaluate patient perceptions of pain treatment with the use of FDA-approved topical/transdermal formulations alone or in combination with neuropathic supplements. The latest analysis of more than 1000 patients ranging in age from 18 to 64 indicates the efficacy of topical analgesic in reducing 45% of opioid usage and a significant reduction of nonopioid drugs to treat chronic pain. Most patients found the topical analgesics convenient and easy to use with minimal reported side effects.
SkinGun Technology Receives Patent Extension
RenovaCare has developed an autologous (self-donated) stem cell therapy for the regeneration of human organs and the US Patent and Trademark Office has granted an additional 30-month extension for the patent, providing protection beyond the year 2035. The SkinGun technology is designed to isolate and spray a liquid suspension of a patient's stem cells onto burns and wounds for rapid self-healing. Independent studies have demonstrated that human skin stem cells sprayed with the SkinGun maintained 97.3% viability. The device and related systems are under development and have not received FDA approval.